Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6
Background
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6 - Fostair® NEXThaler® and pMDI devices

What is the Fostair® Range

The only ICS/LABA fixed-dose combination licensed in asthma and COPD in both pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI). Fostair (beclometasone and formoterol) is available in a 100/6 and a 200/6 formulation.
 

  • Fostair 100/6 is indicated for asthma and COPD (FEV1 <50% predicted normal) in adults1
  • Fostair 100/6 can also be used for Maintenance and Reliever Therapy (MART) for asthma in adults1
  • Fostair 200/6 is indicated for asthma in adults2
Fostair® NEXThaler and pMDI device images for 100/6 & 200/6
Background
Indications
Fostair® NEXThaler and pMDI devices 100/6

Fostair 100/6

Available in both pMDI and DPI

  • Adult asthma
  • MART
  • COPD (FEV1 <50%)
Fostair® NEXThaler and pMDI devices 200/6

Fostair 200/6

Available in both pMDI and DPI

  • Adult asthma

Both Fostair 100/6 and 200/6 are available in pMDI and DPI Fostair NEXThaler.

For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site.
References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair NEXThaler 200/6 Summary of Product Characteristics. Chiesi Limited.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.